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Abstract
The ability to control blood glucose levels is a fundamental component of
vertebrates. In these organisms, blood glucose homeostasis is achieved through a finetuned mechanism that largely involves the secretion of hormones from the endocrine
pancreas into the bloodstream. These hormones include glucagon, which is secreted by
the α cells of the pancreas and initiates the release of glucose into the bloodstream
through gluconeogenesis in the liver, and insulin, which is secreted from the β cells and
signals the uptake of excess blood glucose by the peripheral tissue. Gli-similar 3 (Glis3)
is a transcription factor that has previously been shown to play a critical role in both the
development of β cells and transcriptional activation of the insulin gene. The mechanism
by which the activity of Glis3 is modulated is still largely enigmatic.
The posttranslational modification of proteins by covalent attachment of the small
ubiquitin-like modifier protein (SUMO) has become an interest of many labs in recent
years. This is largely because of the multiple identified substrates for SUMOylation as
well as the wide variety of effects that modification by SUMOylation can have on these
substrates. A yeast two-hybrid assay using the Glis3 N-terminal conserved region as bait
and a murine pancreatic β cell library identified enzymes that play an important role in
the process of SUMOylation as potential Glis3 interactors. Subsequently, potential
SUMOylation sites were identified within a phylogenetically conserved N-terminal
region of Glis3.

vi

We found that Glis3 was SUMOylated by PIAS-family proteins (PIAS1 and
PIASy) at two conserved lysine residues within the N-terminal region of Glis3.
Additionally, it was found that posttranslational modification of Glis3 by SUMOylation
regulated the transactivational activity of Glis3 in a tissue-dependent manner: downregulating target genes in a β cell environment, and up-regulating genes in a non-β cell
environment. These observed effects were due to mechanisms both dependent and
independent of Glis3 SUMOylation as effects were observed after the mutation of the
modified conserved lysine residues.
The transactivation activity of MafA, another transcription factor that plays a
major role in activating target genes in β cells has previously been shown to be
modulated by SUMOylation. It has also been demonstrated previously that MafA and
Glis3 work synergistically to activate target genes. We found that PIASy promoted MafA
SUMOylation which disrupts synergism between MafA and Glis3 at the insulin
promoter.
Finally, we found that chronic exposure of β cells to hyperglycemic conditions
promoted Glis3 and MafA SUMOylation which was coincident with a sharp decrease in
insulin transcription. These data suggest a potential mechanism that could underlie β cell
dysfunction preceding type 2 diabetes and could potentially explain one mechanism by
which insulin secretion is negatively affected in individuals that are incapable of
regulating their blood glucose levels.
Collectively, the results of this project provided novel information regarding
transcriptional control of the insulin gene that is modulated by a combination of blood
glucose levels and posttranslational modification.
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Introduction
The Pancreas
The pancreas is a complex glandular organ composed of three distinct cellular
populations that each perform several important roles in vertebrate physiology. The
differentiated cells rising from these populations include the acinar cells, ductal cells, and
endocrine cells. The acinar cells secrete enzymes into the duodenum that play a major
role in the process of digestion. The ductal cells line the ducts through which these
digestive enzymes travel when they are secreted. The ductal cells also secrete some
products such as bicarbonate and mucins into the digestive tract (Hegyi et al. 2011). The
endocrine cells secrete hormones into the blood stream. This endocrine cell population
contains five different cell types: glucagon-secreting α cells, insulin-secreting β cells,
ghrelin-secreting ε cells, somatostatin-secreting δ cells, and pancreatic polypeptidesecreting PP cells. These endocrine cells are arranged in small groups within the pancreas
called the islets of Langerhans. These islets are closely associated with vasculature and
neurons to facilitate a rapid response to ever-changing physiological conditions. These
islets are largely composed of α and β cells, reflecting the significant role that insulin and
glucagon play in maintaining strict control of blood glucose.
Pancreatic development depends on a complex combination of permissive and
inductive molecular signals from multiple surrounding structures that guide the
differentiation of gut endoderm. Multiple signals are responsible for the initial anteriorposterior patterning of the endoderm. Fibroblast growth factor (FGF) 4, retinoic acid
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(RA) and Wnt/β-catenin are largely responsible for posteriorizing the gut endoderm
(Dessimoz et al. 2006, McLin et al. 2007, Bayha et al. 2009). RA from overlying
mesoderm promotes pancreas specification of the gut endoderm. In zebrafish, it has been
found that one of the most important components of anterior specification of the
endoderm is the degradation of RA by Cyp26a1, which significantly contributes to
defining the pancreatic field (Kinkel et al. 2009). Bone morphogenic protein (BMP) 2
under control of notch signaling is also an important component in specifying the
anterior-posterior axis in zebrafish gut endoderm (Tiso et al. 2002). Although several of
these mechanisms of anterior-posterior axis determination have not been thoroughly
investigated in other organisms, it is likely that these mechanisms are conserved.
In addition to establishing the anterior-posterior field for pancreatic specification,
dorsal-ventral specification of the pancreatic field is also critical. Some of the first signals
that lead to dorsal-ventral patterning of the prospective pancreas are delivered to what
will become the dorsal pancreatic bud. This area of gut endoderm is first within close
proximity to the notochord until the fusion of the paired dorsal aortae displaces the
notochord, leaving the prospective dorsal pancreas associated with cardiac endothelium
(Wessells and Cohen 1967, Spooner et al. 1970, Pictet et al. 1972). Signals from the
notochord include activin-βB and FGF2 (Hebrok et al. 1998). Expression of hedgehog in
the prospective dorsal pancreas ablates dorsal pancreatic development, suggesting that
blockage of sonic hedgehog signaling is critical for dorsal pancreatic development
(Hebrok et al. 1998, 2000). The precise signals coming from the endothelium after
displacement of the notochord during development are not clear. It does appear, however,
that these signals are required for the expression of duodenal homeobox protein 1 (Pdx1),
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a transcription factor that is an early molecular marker of pancreatic fate (Jacquemin et
al. 2009).
The lateral plate mesoderm (LPM) is within close proximity to the prospective
ventral pancreas during early development (Spooner et al. 1970). The specific signals
coming from this tissue are not currently understood, but it has previously been
speculated that ventral pancreatic development mirrors other common developmental
schemes that depend on activin, BMP, and RA. One component of ventral pancreatic
development that sets it apart from dorsal pancreatic development, is the necessity to
block signals coming from the cardiac mesoderm. A major signal that has been
determined to be particularly important in defining the border between the ventral
pancreas and liver by blocking these signals is transforming growth factor (TGF) β
(Wandzioch and Zarat 2009).
After these induction events, cellular proliferation will take place, giving rise to a
dorsal and ventral pancreatic bud. The dorsal pancreatic bud will give rise almost
exclusively to endocrine cells and will form the primary islets. The ventral pancreatic bud
will give rise primarily to acinar and ductal cells in addition to a small number of
endocrine cells. After budding takes place, a stage of rapid cellular growth, division, and
differentiation called primary transition takes place. The ventral and dorsal pancreatic
buds will eventually fuse (Golosow and Grobstein 1962). After this fusion, branching
morphogenesis takes place, forming the ducts through which digestive enzymes will be
transported. The tips of the extending branches express pancreas transcription factor 1
(Ptf1a) and will become acinar cells (Zecchin et al. 2003). The cells directly behind the
Ptf1a-positive tip cells are bipotent trunk progenitors that are capable of developing into

4

ductal cells or endocrine cells, depending on what downstream signals the cells will be
exposed to (Zhou et al. 2007). A stage of development referred to as secondary transition
takes place following branching morphogenesis. This involves rapid and widespread
terminal differentiation of pancreatic progenitor cells into acinar, ductal, or endocrine
cells (Wang et al. 2005).
Blood Glucose Homeostasis
A critical component of physiology is the ability of an organism to maintain a
constant healthy level of blood glucose. Multiple systems are involved in this precise
control of blood glucose. One of the most important components of this process revolves
around the hormones secreted from pancreatic α and β cells. In the event that blood
glucose is high, insulin is secreted into the bloodstream from the β cells. This stimulates
the uptake of excess blood glucose by the peripheral tissue. This glucose is then either
used for energy or stored as fat. When blood glucose is low, glucagon is released into the
bloodstream from the α cells. This stimulates gluconeogenesis in the liver. The glucose
that is released from this process then enters the bloodstream. Diabetes mellitus is
characterized by a disruption in this process, leading to an inability to regulate blood
glucose. This condition is associated with multiple health problems including, blood
vessel damage, neuropathy, and an increased risk of heart disease, strokes, and kidney
failure. Diabetes is a chronic disease, and the cost of managing the symptoms of the
disease has a significant economic impact on the economy of the United States and the
world. In 2012, the cost of treating diabetes in the United States was 245 billion US
dollars (Yang et al. 2013).
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GLIS3, The Gene
Gli-similar (Glis) proteins belong to a subfamily of Krüppel-like zinc finger
transcription factors that are closely related to the Gli and Zic subfamilies (Kinzler et al.
1988, Aruga et al. 1994, Kim et al. 2003, 2005). This family contains three members,
Glis1, Glis2, and Glis3 (Kim et al. 2003, 2005). Within the human genome, the GLIS3
gene is located on chromosome 9p24.2 and spans about 495kb (Kim et al. 2003). GLIS3
contains nine exons and eight introns (Kim et al. 2003). There is about 80% conservation
between mouse and human Glis3 (Kim et al. 2003), as well as other model organisms
such as Xenopus, chicken, and zebrafish. A Glis3 homolog, referred to as both gleeful
(gfl) and lame duck (lmd), has also been identified in Drosophila (Furlong et al. 2001,
Duan et al. 2001).
GLIS3, The Protein
The GLIS3 protein is 90kDa in size. Human GLIS3 contains a domain spanning
exons 2-4 comprised of 5 tandem Cys2-His2 zinc fingers that are separated by a conserved
T/SGEKPY/F amino acid sequence (Kim et al. 2003). This domain is used for interacting
with DNA (Kim et al. 2003). Indeed, previous analyses suggest that all of the zinc fingers
with the exception of ZF1 bind to the major groove of target DNA (Pavletich and Pabo
1993). These interactions between DNA and Glis proteins are strongest at an identified
consensus sequence for a Glis binding site (Fig. 1). Glis proteins will associate with the
consensus sequence for Gli proteins as well, albeit with a lower affinity (Lamar et al.
2001, Nakashima et al. 2002, Kim et al. 2003, Zhang et al. 2002). The consensus
sequence for Glis3 is 5’-(G/C)TGGGGGG(A/C)-3’ (Beak et al. 2008). In addition to the
zinc finger domain, Glis3 also contains a C-terminal transactivation domain that is
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critical in activating the transcription of target genes (Kim et al. 2003, Beak et al. 2008).
Glis3 also contains a large, conserved N-terminal domain. The function of this region is
largely enigmatic, but it appears as though it serves a role in protein-protein interactions
(Kim et al. 2003, ZeRuth et al. 2015).

288

388

Figure 1. Schematic of Glis3 showing the N-terminal conserved region (NCR), zinc
finger domain (ZFD), C-terminal activation domain (CTD), and the Glis binding site
(GlisBS). Numbers indicate amino acid positions. (Adapted from Lichti-Kaiser et al.
2012).
Glis3 Localization
During development, Glis3 is expressed in the kidney, testes, lung, eyes, the
nervous system, limb mesenchyme, pancreas, and osteoblasts (Kim et al. 2003, Beak et
al. 2007). In adult mice, Glis3 is expressed in multiple tissues including the pancreas,
thyroid gland, skeletal muscle, thymus, uterus, ovary, brain, lung, and liver (Kim et al.
2003). Subcellularly, previous studies suggest that Glis3 primarily localizes to the
nucleus and the primary cilium, much like Gli proteins (Kim et al. 2003, Beak et al. 2008,
Hashimoto et al. 2009, Kang et al. 2009a, Haycraft et al. 2005). Disruption or removal of
ZF4 significantly reduces the amount of nuclear localization of Glis3, suggesting that
ZF4 plays an important role in subcellular localization. The primary cilium is important
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in Sonic hedgehog (Shh-) and Wnt-mediated signaling, and dysfunctions in the cilia have
been linked to several pathologies, referred to as ciliopathies (Oro 2007, Rohatgi et al.
2007, Corbit et al. 2008, Veland et al. 2009, Bisgrove and Yost 2006, Hildebrandt et al.
2009). Glis3 plays an important role in both developing and adult cells. One target gene
that Glis3 plays a major role in activating is the insulin gene (Senee et al. 2006, Watanabe
et al. 2009, Kang et al. 2009b, Yang et al. 2009, Beak et al. 2007, Kim et al. 2003).
Glis3-Associated Pathologies
Multiple diseases have been linked to dysfunctional Glis3. Human GLIS3
mutations have been implicated in a syndrome referred to as neonatal diabetes and
hypothyroidism (NDH), characterized by hyperglycemia, hypoinsulemia, neonatal
diabetes, as well as elevated thyroid stimulating hormone (TSH) (Senee et al. 2006).
NDH can be accompanied by facial abnormalities, cholestasis, progressive hepatic
fibrosis, and congenital glaucoma (Taha et al. 2003, Senee et al. 2006). GLIS3 mutations
also result in polycystic kidney disease, a syndrome characterized by the progressive
development of massive kidney cysts capable of leading to kidney failure (Taha et al.
2003, Senee et al. 2006). The mechanism behind the development of these cysts is
currently unknown, but it could involve a developmental role of the planar cell polarity
pathway due to the finding the Glis3 is expressed in the metanephric mesenchyme during
development (Kim et al. 2003). Glis3 null mice display a similar phenotype to human
NDH patients, including polycystic kidneys, dilated pancreatic ducts, and smaller,
misshapen pancreatic islets containing significantly fewer β cells than wild-type mice
(Kang et al. 2009b, Watanabe et al. 2009). This suggests that Glis3 could play an
important role in endocrine pancreatic development, particularly in directing the
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differentiation of β cells. A human genome-wide association study has identified GLIS3
as a risk locus for both type 1 and type 2 diabetes (Barrett et al. 2009, Boesgaard et al.
2010, Dupuis et al. 2010).
Glis3-Mediated Gene Regulation
The observation that Glis3 localizes to the primary cilium contributed to
constructing the current hypothetical model of how Glis3-mediated activation or
repression of target genes is modulated (Kang et al. 2009a, Haycraft et al. 2005). The
primary cilium is a cellular organelle surrounded by a membrane that is continuous with
the phospholipid bilayer of the cell with an axoneme formed by nine pairs of
microtubules extending its length (Bisgrove and Yost 2006, Berbari et al. 2009).
Transport proteins are important for moving proteins in and out of the cilium, a process
referred to as intraflagellar transport (IFT) (Rosenbaum and Witman 2002, Bisgrove and
Yost 2006, Berbari et al. 2009). This hypothetical model proposes a mechanism that is
similar to the Shh/Gli3 protein pathway. In this pathway, the Patched (Ptch)
transmembrane protein is the receptor for the Shh ligand (Rohatgi et al. 2007). When no
Shh is present in an environment, Ptch represses another transmembrane protein,
Smoothened (Smo) (Rohatgi et al. 2007). This leads to Gli3 being cleaved, which
removes the transactivation domain but leaves the ZF domain, generating an inhibitor
(Haycraft et al. 2005). When Shh is present in an environment, it will bind to Ptch. Ptch
will then no longer repress Smo, so Smo will build up and prevent the cleaving of Gli3.
This leads to an accumulation of an uncleaved, activator form of Gli3. This hypothetical
model is supported by data that suggest that Glis3 is capable of acting as an activator or a
repressor (Kim et al. 2003). In the Shh/Gli3 pathway, IFT is critical in transporting Gli3
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into the cilia, where it can be processed and can then relocate to the nucleus to repress or
activate target genes (Haycraft et al. 2005).
The mechanism by which Glis3 activates or represses the activity of target genes
is currently not completely understood. It has previously been shown that Glis3 interacts
with various coactivators that modify chromatin at the site of a target gene to activate or
repress the target (ZeRuth et al. 2013). Indeed, various protein-protein interactions appear
to play a significant role in the activity of Glis3 as an activator or a repressor. ZeRuth et
al. (2013) showed that the ability of Glis3 to recruit Creb-Binding Protein (CBP/p300) to
the insulin promotor is critical for the synergistic activity of Pdx1, neurogenic
differentiation 1 (NeuroD1), and v-maf musculoaponeurotic fibrosarcoma oncogene
homolog A (MafA) in activating the insulin gene (Pashavaria et al. 1997, Ohneda et al.
2000, Qiu et al. 1998, Zhao et al. 2005, Naya et al. 1997). Glis3 has also been shown to
interact with WW domain-containing transcription regulator 1 (Wwtr1) (Kang et al.
2009a). Wwtr1 can interact with various other transcription factors to act as a coactivator
or corepressor of target genes (Hong et al. 2005, Hong and Yaffe 2006).
MafA
MafA is a member of the large Maf family of transcription factors, all of which
contain an N-terminal transactivation domain and a C-terminal basic leucine-zipper DNA
binding domain (Matsuoka et al. 2003). Much like Glis3, MafA is highly conserved
across species, presumably because of the important role that it plays in regulating the
transcription of target genes (Olbrot et al. 2002). MafA is almost exclusively expressed in
hormone-producing cells, a characteristic not observed in many other transcription
factors that play a major role in insulin transcription (Nishimura et al. 2006). Another
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distinction that sets MafA apart from related β cell transcription factors is the apparent
lack of importance of MafA in the development of the pancreas. Complete knockout as
well as conditional pancreatic knockout of MafA in mice does not affect pancreatic
development, but these mice do display a severe reduction in expression of key β cell
genes and develop diabetes by 12 weeks after birth (Artner et al. 2010, Zhang et al.
2005). These knockouts, as well as other studies, suggest that MafA becomes more
important as organisms advance towards adulthood (Aguayo-Mazzucato et al. 2011).
Posttranslational Modifications
Post-translational modification (PTM) involves the changes made to a protein
following or during translation. Some of the most common PTMs include
phosphorylation, acetylation, N-linked glycosylation, amidation, hydroxylation, and
methylation (Khoury et al. 2011). Cleavage of particular functional domains of proteins
by proteinases is another common PTM. These PTMs can have a vast array of effects on
their target protein. The multitude of potential modifications and their dynamic nature
allows for extreme fine tuning of protein function, adding an entire layer of complexity to
the proteome of virtually every living organism. PTMs can affect protein stability,
subcellular localization, regulatory activity, interactions with DNA, and protein folding
by the addition or removal of functional groups (Kleinsmith et al. 1966, Wilkinson et al.
1980, McNabb and Courtney 1992, Allfrey et al. 1964, Agnetti et al. 2013). Various
characteristics of proteins can also be altered by PTM via precise cleaving by
proteasomes. This type of effect is observed in the Shh/Gli pathway where the
transactivation domain of Gli transcription factors is removed in the absence of Shh. The
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DNA-binding domain remains on the Gli protein, effectively turning the transcription
factor into a repressor.
A field that is only recently being truly recognized for the important role that it
plays in gene regulation is epigenetic control of gene regulation. This process depends on
the PTM of histone proteins within chromatin. Some of the most common modifications
made to these histone proteins are acetylation and methylation, which are able to allow a
gene to be activated or repressed respectively by altering the binding efficiency of the
histone to the DNA (Allfrey et al. 1964). Adding an additional degree of complexity to
the concept of PTM, the activity of many enzymes responsible for performing the PTMs
is modulated by PTMs of the enzymes themselves (Chuah and Pallen 1989, Chan et al.
2010, Bhattacharyya et al. 2016).
PTMs are an area of interest that continue to show a potential to elucidate the
transcriptional regulatory activity of both Glis3 and MafA, as well as the enzymes that
facilitate these modifications. Zeruth et al. (2015) have found that HECT E3 ubiquitin
ligase plays a role in the poly-ubiquitination and subsequent destabilization of Glis3,
negatively regulating the transcriptional activity of Glis3 target genes. Additionally,
MafA has been shown to undergo posttranslational modification by phosphorylation,
affecting its transactivational potential and protein stability (Rocques et al. 2007, Guo et
al. 2008, Han et al. 2007, Zhao et al. 2005). It is likely that additional post-translational
modifications and associations also take place in order to control the activity of these
proteins and that these posttranslational modifications could provide further insights into
multiple common diseases.
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SUMOylation
Post-translational modifications of specific lysine residues on protein substrates
by the small ubiquitin-like modifying protein (SUMO) are essential to multiple cellular
processes, including critical steps of the cell cycle such as chromosome segregation
(Nacerddine et al. 2005). There are three members of the SUMO family, denoted
SUMO1, SUMO2, and SUMO3.
The process of conjugating SUMO to substrates is analogous to that of
ubiquitination, and this process involves several steps (Desterro et al. 1997). The initial
step of SUMOylation depends on the activation of pro-SUMO by a protease belonging to
the sentrin-like protease (SENP) family (Cheng et al. 2007). There are seven members of
the SENP family, but SENP1 appears to be the most important enzyme for activating
SUMO by proteolytically processing its C-terminus (Cheng et al. 2007). The next step of
the SUMOylation process involves activation of SUMO by an E1 SAE1/SAE2
homodimer enzyme by its formation of a disulfide bridge with SUMO (Johnson et al.
1997, Desterro et al. 1999). The next step of SUMOylation in vertebrates is dependent on
a single E2 conjugase, Ubc9 (Desterro et al. 1997). Ubc9 displaces SAE1/SAE2, forming
a new disulfide bridge with SUMO (Desteroo et al. 1997). SUMOylation also often relies
on an E3 ligase which will conjugate SUMO to the substrate protein. In mammals, this
E3 ligase belongs to a family that is the homolog to the Siz family of proteins found in
yeast, the protein inhibitor of activated STAT (PIAS) family (Nishida and Yasuda 2002,
Johnson and Gupta 2001, Sachdev et al. 2001, Kahyo et al. 2001, Kotaja et al. 2002,
Schmidt and Muller 2002, Mabb et al. 2006, Shalizi et al. 2007, Dawlaty et al. 2008,
Parker et al. 2008). The process of SUMOylation is dynamic. SUMO can be
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deconjugated from its substrate by SENPs and recycled in the conjugation to a different
substrate (Gong et al. 1999, 2000, Hang and Dasso 2002, Bailey and O’Hare 2004).
While it has been discovered that many proteins are SUMOylated, the effect that this
process has on the substrate is largely unknown in most cases. SUMOylation has been
observed affecting protein stability as well as initiating specific subcellular localization,
protein-protein interactions, protein-DNA interactions, and both enhancing and
repressing the activity of target substrates (Matunis et al. 1998, Goodson et al. 2001, Bies
et al. 2002, Pichler and Melchoir 2002, Pichler et al. 2002, Abdel-Hafiz et al. 2002, Ross
et al. 2002, Ihara et al. 2005). Additionally, SUMOylation has been implicated in both the
enhanced and repressed activity of transcription factors (Bies et al. 2002, Abdel-Hafiz et
al. 2002, Ihara et al. 2005, Muller et al. 2000, Hofmann et al. 2000, Eloranta and Hurst
2002, Bossis et al. 2005, Cheng et al. 2007). There also appears to be complex interplay
between SUMOylation and other substrate modifications such as ubiquitination,
phosphorylation, and acetylation (Desterro et al. 1998, Muller et al. 1998, Hoege et al.
2002, Sapetschnig et al. 2002, Hietakangas et al. 2003, Pichler et al. 2005, StankovicValentin et al. 2007). Phosphorylation is one of the most studied in its affect in relation to
SUMOylation. Phosphorylation appears to be yet another level of regulation for the
process of SUMOylation due to the fact that it can either positively or negatively regulate
SUMOylation, depending on the substrate (Muller et al. 1998, Gupta et al. 2008, Gresko
et al. 2009). Previous studies suggest that the effect of phosphorylation-dependent
SUMOylation is particularly important in the case of transcription factors (Gregoire et al.
2006, Hietakangas et al. 2006). Post-translational modification by SUMO is further
complicated by the ability of the E3 ligase enzymes themselves to be SUMOylated,
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which can modulate their function and specificity in ligating SUMO to substrates (Ihara
et al. 2005).
Pathologies Associated with SUMOylation
Dysfunctions in the SUMO pathway have been linked to physiological disruptions
that can lead to the development of diabetes (Kishi et al. 2002, Shao and Cobb 2009,
Kanai et al. 2010, Belaguli et al. 2012). It has been shown that the function of certain key
transcription factors important in regulating insulin transcription and β cell development,
including Pdx1, MafA, and forkhead box protein A2 (FoxA2), are dependent on
SUMOylation (Kishi et al. 2002, Shao and Cobb 2009, Kanai et al. 2010, Belaguli et al.
2012). These studies have shown the variable effects that SUMOylation can have on a
substrate protein. SUMOylation of MafA has been shown to negatively regulate its
transcriptional activity (Shao and Cobb 2009, Kanai et al. 2010). SUMOylation of
FoxA2, however, stabilizes the protein and leads to increased transactivational activity of
the protein and higher levels of Pdx1, a key transcription factor and target gene of FoxA2
(Belaguli et al. 2012). Furthermore, SUMOylation of Pdx1 has shown to be essential for
its proper subcellular localization (Kishi et al. 2002).
Two sites within the Glis3 N-terminal conserved region that conform to the
established SUMOylation motif, (ψKxE), where ψ is a hydrophobic residue and x is any
amino acid, were found starting at amino acids 223 and 429 (Rodriguez et al. 2001,
Sampson et al. 2001). This led to the formation of the hypothesis that Glis3 is being
SUMOylated, and this posttranslational modification modulates the activity of Glis3 and
a transcription factor in pancreatic β cells. If it is found that Glis3 activity is regulated by
SUMOylation, this would give further insight into the complex mechanism of insulin
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secretion and blood glucose homeostasis and could serve as a potential target for future
therapeutic efforts to treat individuals incapable of maintaining healthy blood glucose
levels.
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Materials and Methods
Cells and Growth Conditions
Rat insulinoma INS-1832/13 cells, a generous gift from Dr. H. Hohmeier (Duke
University), were maintained in RPMI 1640 supplemented with 10% fetal calf serum,
10mM HEPES, 2mM glutamine, 1mM sodium pyruvate, 100 units/ml penicillin, 100
µg/ml streptomycin, and 50 µM 2-mercaptoethanol. HEK293T cells were purchased from
ATCC and cultured in DMEM containing 100 units/ml penicillin, 100 µg/ml
streptomycin, and 10% FBS. BRIN-BD11 cells were purchased from the European
Collection of Authenticated Cell Cultures (ECACC) and were maintained in RPMI 1640
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, and 10% FBS.
Generation of Plasmids and Constructs
The generation of p3xFLAG-CMV10-Glis3, ΔC480, ΔN222, ΔN288, ΔN333,
ΔN355, ΔN388, ΔN496, ΔC653, and ZF3 mut were described previously (Kang et al.
2009b, ZeRuth et al. 2011, 2015). The luciferase reporter constructs p-mIP-696-Luc, phINS-700-Luc, p-mIP-UAS-Luc, p-mIP-696(C-box), p-(UAS)5-Luc, pM-Glis3(1-653),
pM-Glis3(653-935), and VP16-Glis3(480-653) were also described previously (ZeRuth et
al. 2013, Kang et al. 2009b, ZeRuth et al. 2015, 2011). pCMV-Myc-PIAS1, PIASy, and
Ubc9 were generated by PCR amplifying the full length cDNA and directionally cloning
into pCMV-Myc (Clontech) using EcoRI and XhoI restriction enzymes. pM and VP16
PIAS1 and PIASy constructs were made by PCR amplifying the indicated regions and
cloning into pM or VP16 vector (Clontech) using EcoRI and BamHI restriction enzymes.
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p3xFLAG-CMV10-MafA was described previously (ZeRuth et al. 2013). pcDNA3 HASumo1 WT was a gift from Guy Salvesen (Addgene plasmid # 48966) and Flag-SENP1
was a gift from Edward Yeh (Addgene plasmid # 17357) and were described previously
(Bekes et al. 2011, Cheng et al. 2007). 3xFLAG-Glis3 S305A/D, S3057A/D, S310A/D,
and S343A as well as 3xFLAG-Glis3 K224R and K430R mutants were generated by sitedirected in vitro mutagenesis using p3xFLAG-CMV10-Glis3 as template. All mutants
were verified by sequencing. FLAG-Glis3:SUMO fusion constructs were generated by
overlap-extension-synthesis PCR (OES-PCR) using primer sets shown in Table 1.
Briefly, the region encoding Glis3 amino acids 1-223 or 1-429 were amplified by PCR
with a 5’ EcoRI overhang and 3’ overhangs overlapping the 5’ portion of SUMO1 using
primers: Glis3 EcoRI F, SUMO224R, and 430-SUMO-R.

Primer Name
Primer Sequence (5’ to 3’)
Glis3 EcoRI F
ATGCGAATTCAAATGGAAGGTCATGT
224-SUMO-R
TGCCTCCTGGTCAGACACACTCAAGGCTGA
430-SUMO-R
TGCCTCCTGGTCAGAGAGCATGTTGGCTGT
SUMO1-224 F
TCAGCCTTGAGTGTGTCTGACCAGGAGGCA
SUMO1-224R
CTGAGACCACTCTTGTTGTTCCTGATAAAC
SUMO1-430F
ACAGCCAACATGCTCTCTGACCAGGAGGCA
SUMO1-430R
CTCCAGGCGCTCTGTTTGTTCCTGATAAAC
224-SUMO F
GTTTATCAGGAACAACAAGAGTGGTCTCAG
430-SUMO F
GTTTATCAGGAACAAACAGAGCGCCTGGAG
Glis3-BamHI R
ATGCGGATCCTCAGCCTTCGGTATA
Table 1. List of primers used for OES cloning.

SUMO1 was PCR amplified with a 5’ and a 3’ overhang overlapping Glis3 at the
indicated regions using primers: SUMO1-224 F and SUMO1-224R or SUMO1-430F and
SUMO1-430R. The 3’ portion of Glis3 encoding amino acids 225-935 or 431-935 was
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amplified with a 5’ overhang overlapping the 3’ portion of SUMO1 and a 3’ BamHI
overhang using primers: 224-SUMO F or 430-SUMO F and Glis3-BamHI R.
PCR products were cleaned up using a GenElute PCR Cleanup Kit (Sigma Aldrich) and
added in equimolar concentrations along with dNTPs and Pfu TURBO (Agilent
Technologies) and run in a thermal cycler under programmed 95° C 2 min, followed by
20 cycles of 95° C 30 sec; 60° C 30 sec; 72° C 3 min. 5 µl of the resulting product was
removed and used as template for a subsequent PCR reaction this time including 0.4 µM
FLAG Glis3 EcoRI F primer and Glis3-BamHI R primer using conditions 95° C 2 min
followed by 40 cycles of 95° C 30 sec; 55° C 30 sec; 72° C 3 min. The correct sized
bands were gel purified in a 1% agarose gel and subsequently digested with EcoRI and
BamHI. Digested inserts were directionally cloned into p3xFLAG-CMV10 plasmid
(Sigma Aldrich) cut with identical enzymes. Positive clones were analyzed by restriction
analysis and verified by sequencing.
Reporter Assays
Cells were plated in 12-well dishes at 1 x 105 cells/well and incubated for 24 h at
37 °C. Cells were subsequently transfected with the indicated reporter, pCMV-βgalactosidase, and the indicated expression vector in serum-free medium without
antibiotic using Lipofectamine 3000 (Invitrogen) per the manufacturer’s instructions.
Each transfection was carried out in triplicate. Cells were harvested after 48 h by scraping
them directly into 125 ul of reporter lysis buffer, and luciferase activity was measured
using a luciferase assay kit (Promega). β-Galactosidase levels were measured using a
luminometric β-galactosidase detection kit (Clontech) following the manufacturer’s
protocol. Each data point was assayed in triplicate, and each experiment was performed
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at least twice. Relative luciferase activity was calculated. All values underwent analysis
of variance and Tukey-Kramer comparison tests using InStat software (GraphPad
Software Inc.), and data are presented as mean +/- S.E. Mammalian two-hybrid assays
were performed with HEK293T cells plated in 12-well dishes at 1 x 105 cells/well and
incubated for 24 h at 37 °C. Cells were subsequently transfected with pM or VP16 empty
vector (Clontech) or the indicated chimera, pFR-Luc, and pCMV-β-gal diluted in serumfree media lacking antibiotic and incubated with Lipofectamine 3000 reagent according
to the manufacturer’s protocol (Invitrogen). Cells were harvested, and luciferase assays
were conducted and analyzed as reported above.
Co-Immunoprecipitation Assays
Cells were transiently transfected with the specified plasmids using
Lipofectamine 3000 reagent (Invitrogen) following the manufacturer’s protocol. 48 h
after transfection, cells were harvested by scraping in radioimmune precipitation assay
(RIPA) buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM sodium
molybdate, and 0.5% Nonidet P-40) containing protease inhibitor cocktails I and II
(Sigma). Cell lysates were centrifuged at 16,000 x g for 10 min at 4 °C, and a fraction of
the supernatant was stored at -80 °C for the input fractions. The remaining supernatant
was incubated at RT for 15 min with DynaBeads (Invitrogen) conjugated to the indicated
antibody. Beads were washed three times with 200 µl of ice-cold PBS containing
protease inhibitor and proteins were released from the beads by boiling for 5 min in the
presence of 1x Laemmli buffer supplemented with 2.5% 2-Mercaptoethanol. Input and
immunoprecipitated proteins were examined by Western blot analysis using mouse antiM2 FLAG (Sigma Aldrich), mouse anti-Myc antibody (Invitrogen), rat anti HA antibody
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(Roche), rabbit anti-PIAS4 (PIASy) antibody (Cell Signaling Technologies), rabbit antiSUMO1 (Cell Signaling Technologies), or mouse anti-SUMO2/3 antibody
(Cytoskeleton) and the appropriate HRP-conjugated secondary antibodies. Blots were
processed and analyzed using an Amersham Imager 600 digital imager (GE Life
Sciences).
Western Blot Analysis and Protein Quantification
Proteins were resolved by SDS-PAGE and then transferred to PVDF membrane
(Invitrogen) by electrophoresis. Immunostaining was performed with the indicated
antibody at either 4 °C for 18 h or 22 °C for 1 h in BLOTTO reagent (5% nonfat dry milk
dissolved in 50 mM Tris, 0.2% Tween 20, and 150 mM NaCl). Blots were subjected to
three 10-min washes in TTBS (50 mM Tris, 0.2% Tween 20, and 150 mM NaCl), and
bands were detected by enhanced chemiluminescence following the manufacturer’s
protocol (GE Healthcare). Proteins were quantified using ImageQuantTL software (GE
Life Sciences) The mean intensity and pixel count of experimental bands were multiplied
and divided by the mean intensity multiplied by the pixel count of GAPDH bands used
for normalization. All samples were run in duplicate and all experiments performed at
least twice. Data shown are the average of duplicate samples +/- S.E.
Quantitative Reverse Transcriptase Real-Time PCR Analysis
INS1 832/13 or BRIN-BD11 cells were transiently transfected with the indicated
constructs using Lipofectamine 3000 reagent following the manufacturer’s protocol
(Invitrogen). RNA was isolated from the cells after 48 h using a GenElute Mammalian
Total RNA miniprep kit (Sigma Aldrich) according to the manufacturer’s specifications.
Equal amounts of RNA were used to generate cDNA using a high capacity cDNA kit
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(Applied Biosystems), and cDNA was analyzed by quantitative real-time PCR using
PowerUP SYBR green master mix (ThermoFisher Scientific). All qRT-PCR was
performed in triplicate using an Applied Biosystems 7500 real time PCR system. Primers
used are listed in Table 2. The average Ct from triplicate samples was normalized against
the average Ct of 18S rRNA.

Gene target

Primer sequence (5’ to 3’)

F – CCTGCTCGTCCTCTGGGAGCCCAAG
R - CTCCAGTGCCAAGGTCTGAAGATCC
rIns2
F – CCTGCTCATCCTCTGGGAGCCCCGC
R - CTCCAGTGCCAAGGTCTGAAGGTCA
rPIAS1
F- CTACCAGCCTACGGGTTTCG
R - GAACAGGTAAGTGCCCGACA
rPIASy
F – ATAGATGGGCTGCTGTCGAAGA
R - ATTGGGCGCCATGAACCTT
rGlis3
F – GTGAAGGCACATTCTTCCAAAGA
R - GGAGATCTGGATGGAGCTCAGT
FLAG-Glis3 F – TGGACTACAAAGACCATGACGG
R - GGGCTCTGATGGGAGGGATA
18s rRNA
F – GTAACCCGTTGAACCCCATT
R - CCATCCAATCGGTAGTAGCG
Table 2. List of primers used for RT-PCR.
rIns1

Immunocytochemistry and Microscopy
BRIN-BD11 cells were grown on 22 mm poly-L-lysine coated glass coverslips in
35 mm culture dishes for 48 h until cells were 70-80% confluent. The coverslips were
washed in PBS and fixed for 15 min in 4% p-formaldehyde before being permeabilized in
0.2% Triton-X-100 for 7 min. Cells were blocked in Superblock (ThermoFisher
Scientific) for 15 min and then stained with the indicated antibody overnight at 4° C.
Cells were stained with anti-mouse AlexaFluor 594 secondary antibody (ThermoFisher
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Scientific) for 30 min and mounted on glass microscope slides using Prolong Diamond
anti-fade with DAPI (Life Technologies) and sealed with clear nail polish. Coverslips
were observed on a Leica DMi8 fluorescence inverted microscope (Leica Microsystems)
and images were captured using a DFC7000T cooled fluorescence camera and LAS X
Expert software (Leica Microsystems).
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Results
Glis3 Interacts with PIAS-Family Proteins
In order to identify proteins that interact with the Glis3 N-terminus, tandemaffinity-pulldown (TAP) of the Glis3 N-terminus followed by GelC-MS/MS analysis was
performed previously in HEK293F cells. In addition, a yeast-two-hybrid analysis was
conducted using the Glis3 N-terminus as bait to identify interacting proteins from a
murine pancreatic beta cell prey library (ZeRuth et al. 2015). These studies identified
several proteins implicated in the SUMO conjugation pathway including the SUMOconjugating protein Ubc9 (UBE2I) and members of the protein inhibitor of activated
STAT (PIAS)-family, which have been shown to act as E3 SUMO-ligases (Rytinki et al.
2009) as putative Glis3-interacting proteins. Co-immunoprecipitation experiments
performed in HEK293T cells co-expressing FLAG-Glis3 and Myc-tagged Ubc9, PIAS1,
or PIASy, however, showed only a weak interaction between Glis3 and the PIAS-family
proteins (Fig. 2A). Similar results were obtained when a mammalian 2-hybrid assay was
performed in HEK293T cells using the N-terminus of Glis3 (aa 1-653) fused to the Gal4
DBD and full length PIASy fused to the Gal4 AD to drive luciferase expression under
control of the Gal4-responsive UAS region. These experiments showed a modest 1.5-fold
increase in luciferase expression when the chimeric proteins were co-expressed (Fig 2B).
FLAG-Glis3 was additionally immunoprecipitated in HEK293T cells as well as the
pancreatic hybridoma cell line BRIN-BD11 and immunoblots were stained with
antibodies targeting endogenous PIAS proteins. In this context, no endogenous PIAS
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proteins could be detected in the immunoprecipitated fractions (Fig 2C-D), likely due to a
limited amount of endogenous PIAS proteins. Collectively, these data indicate that Glis3
may form weak or unstable interactions with PIAS-family proteins.

Figure 2. Glis3 weakly interacts with PIASy and PIAS1. A. HEK293T cells were
transfected with FLAG-Glis3 and either Myc-Ubc9, Myc-PIAS1, or Myc-PIASy as
indicated. Co-immunoprecipitation was performed using a mouse anti-Myc antibody and
immunoprecipitated proteins were examined by Western blot analysis using anti-M2
FLAG or anti-Myc primary and goat anti-mouse-HRP secondary antibodies. B.
HEK293T cells were co-transfected with the pFR-Luc reporter and the indicated pM and
VP16 plasmid DNA. 48 h later cells were assayed for luciferase and β-galactosidase
activities, and the relative Luc activity was calculated and plotted. Each bar represents
mean +/- S.E. *, statistically different from pM or VP16 empty vector controls p < 0.05.
nRLU, normalized relative luc units. C-D. HEK293T (C.) or BRIN-BD11 (D.) cells were
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transfected with FLAG empty vector or FLAG-Glis3 as indicated. Coimmunoprecipitation was performed using an anti-M2 FLAG antibody.
Immunoprecipitated and input fractions were analyzed by Western blotting using a rabbit
anti-PIASy antibody, rabbit anti-PIAS1 antibody or mouse anti-M2 FLAG antibody and
the appropriate HRP-conjugated secondary antibodies.
PIAS-Family Proteins SUMOylate Glis3 at Lys224 and Lys430
Given the role of PIAS proteins in mediating SUMOylation of target proteins, coimmunoprecipitation assays were performed in HEK293T cells expressing FLAG-Glis3
and HA-SUMO1 in the presence or absence of PIAS1 or PIASy. Protein complexes were
pulled down using an anti-HA antibody and SUMOylation of Glis3 was analyzed by
Western blotting using anti-M2 FLAG antibody. As seen in Fig. 3A, both members of the
PIAS family promoted SUMOylation of exogenous Glis3 with relatively similar efficacy.
To date, Ubc9 is the only SUMO-conjugating enzyme that has been identified in
mammals and appears to be the sole E2 enzyme used in the SUMO-conjugation pathway
(Gareau and Lima 2010). Co-expression of Ubc9 with HA-SUMO and FLAG-Glis3 in
HEK293T cells modestly increased Glis3 SUMOylation compared to HA-SUMO and
FLAG Glis3 alone (Fig. 3B). This was in stark contrast to the role PIAS1 and PIASy
played in mediating Glis3 SUMOylation when co-expressed with HA-SUMO and FLAGGlis3 (Fig. 3A-B). These results were not surprising as PIAS-family proteins are more
likely to be limiting factors in regulating Glis3-SUMOylation than Ubc9, which is
ubiquitously expressed (Kovalenko et al. 1996). Intriguingly, while simultaneous coexpression of Ubc9 and PIASy significantly increased the observed level of Glis3
SUMOylation compared to either protein alone, coincident expression of Ubc9 and
PIAS1 virtually eliminated all detectable Glis3 SUMOylation. Nearly identical results
were obtained when the experiment was repeated in the pancreatic hybridoma cell line,
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BRIN-BD11 (Fig. 3B), suggesting the observation is not cell- or tissue-specific. The lack
of Glis3 SUMOylation under these conditions appears to be the result of a significant
decrease in PIAS1 expression in the presence of both exogenous Ubc9 and HA-SUMO
(Fig. 3B-C). PIAS1 degradation did not appear to require Glis3 as the protein was
degraded in its presence or absence (Fig. 3C) and therefore the underlying mechanism of
PIAS1 degradation was not investigated further. However, for further experiments
requiring co-expression of Ubc9, SUMO, and PIAS proteins, we used PIASy to simplify
data analysis. The SUMO-specific protease SENP1 was capable of effectively
deconjugating SUMO from Glis3 as demonstrated in Fig. 3D when SENP1 was coexpressed with FLAG-Glis3, HA-SUMO1, Ubc9, and PIASy. Together, these data
suggest that the E2 SUMO conjugase, Ubc9 along with the E3 SUMO ligases, PIAS1 and
PIASy are capable of reversibly modifying Glis3 with SUMO.
SUMO modification typically occurs at a lysine residue within the target substrate
that conforms to the consensus sequence ψKxE where ψ is a hydrophobic residue and x is
any amino acid (Duprez et al. 1999, Rodriguez et al. 2001, Sterndorf et al. 1999,
Sampson et al. 2001). Analysis of Glis3 using SUMOplot software (www.abgent.com)
revealed two high probability consensus SUMO motifs located at Lys224 and Lys430, both
located within the N-terminus of the protein and conserved between murine and human
Glis3 (Fig. 3E). In order to determine whether SUMO was attached to these residues
within Glis3, each of the lysines was mutated to arginine either alone or in combination.
While co-expression of HA-SUMO and PIASy resulted in two distinct bands
representing SUMOylated Glis3, mutation of Lys224 to Arg resulted in a decrease of the
higher molecular weight band (Fig. 3F). Mutation of Lys430 to Arg similarly resulted in
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the elimination of the higher molecular weight band and additionally dramatically
reduced the lower weight band representing SUMOylated Glis3. Simultaneous mutation
of both lysine residues abolished all detectable Glis3 SUMOylation. These results
indicate that PIAS family proteins can mediate the attachment of SUMO1 to Glis3 at
either Lys224, Lys430, or both simultaneously; however, SUMOylation of Glis3 at Lys430
may promote subsequent SUMOylation of full-length Glis3 at Lys224. Indeed, it has
previously been demonstrated that SUMOylation of a target protein at one motif can
subsequently influence SUMO-Ubc9 interactions at additional motifs (Gareau and Lima
2010, Brozovic et al. 2006).
The Glis3 SUMOylation motifs are conserved between human and mouse Glis3
but are absent in zebrafish glis3. To verify that human GLIS3 can also be modified by
SUMO, co-IP was performed using murine, human, or Danio Glis3 in HEK293T cells.
As expected, both human and mouse Glis3 were SUMOylated by PIASy and Ubc9 while
no modification of zebrafish glis3 was observed (Fig. 3G). These results demonstrate that
modification of Glis3 by SUMO appears to be conserved among mammals and may have
evolved following the split that would give rise to tetrapods and teleost fishes.
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Figure 3. Glis3 is SUMOylated by PIAS-family proteins at Lys224 and Lys430. A-B.
HEK293T or BRIN-BD11 cells were transfected with FLAG empty vector or FLAG
Glis3 along with HA-SUMO1, Myc Ubc9, Myc PIAS1, or Myc PIASy as indicated. After
48 h, co-immunoprecipitation was performed using a rat anti-HA antibody and
immunoprecipitated proteins were examined by Western blot analysis using mouse antiM2 FLAG or anti-Myc primary and goat anti-mouse-HRP secondary antibodies. C.
HEK293T cells were transfected with the indicated plasmids. Cells were treated with 10
ug/ml cycloheximide for 5 h prior to harvest. Proteins were separated by SDS-PAGE and
analyzed by Western blotting using the specified antibodies. GAPDH is shown as an
internal control. D. HEK293T cells were transfected with the indicated plasmids. After 48
h, co-immunoprecipitation was performed using a rat anti-HA antibody and
immunoprecipitated proteins were examined by Western blot analysis using mouse antiMyc primary and goat anti-mouse-HRP secondary antibodies. E. Schematic
representation of Glis3. Relative position and sequence of putative SUMOylation motifs
are shown. NCR, N-terminal conserved region; ZFD, zinc finger domain; TAD,
transactivation domain. F-G. HEK293T cells were transfected with the indicated
plasmids. Co-immunoprecipitation was carried out using a mouse anti-M2 FLAG
antibody. Proteins were analyzed by Western blotting using a rat anti-HA antibody, mouse
anti-M2 FLAG, or anti-Myc antibodies as indicated.
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Glis3 is SUMOylated by SUMO1, SUMO2, and SUMO3
To investigate whether PIAS proteins preferentially modify Glis3 with SUMO 1,
2, or 3, co-IP was performed in HEK293T cells expressing FLAG-Glis3 and Myc-PIASy
along with GFP-tagged SUMO1, SUMO2, or SUMO3. While Glis3 appeared to be
mono- or di-SUMOylated by SUMO1, polySUMOylation was evident when Glis3 was
co-expressed with PIASy and SUMO2 or SUMO3 (Fig. 4A). PolySUMOylation of Glis3
appeared to target the protein for proteasomal degradation because Glis3 SUMOylated by
SUMO 2 or SUMO3 was stabilized by the proteasome inhibitor, MG132. MG132
treatment had little or no effect on Glis3 modified by SUMO1. In order to determine
whether SUMOylation of Glis3 could be detected endogenously, FLAG-Glis3 or the
Lys224/Lys430 double mutant was stably expressed in BRIN-BD11 cells and pulled down
using an anti- FLAG M2 antibody. Immunoprecipitated fractions were then analyzed by
Western blotting using an antibody specific to SUMO1. Glis3 was not found to be
modified by endogenous SUMO1 in the cells (Fig. 4B). SUMO1 modified Glis3 was also
not detected in HEK293T cells in the presence or absence of exogenous PIASy and Ubc9
(Fig 4C, lanes 2 and 3). SUMOylated Glis3 was evident, however, when exogenous HASUMO1 was co-expressed along with PIASy and Ubc9 and could be detected in the
immunoprecipitated fractions by antibodies targeting the HA tag or SUMO1 (Fig 4C,
lane 4). These data suggest that only a small proportion, if any of exogenous Glis3 is
modified by SUMO1 under normal conditions in HEK293T or BRIN-BD11 cells.
However, SUMO2/3 modified Glis3 could be observed in MG132-treated BRIN-BD11
cells stably expressing FLAG-Glis3 in the presence or absence of exogenous PIAS1 or
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PIASy (Fig. 4D). No SUMO2/3 modified Glis3 could be detected in BRIN-BD11 cells
stably overexpressing the Lys224/Lys430 double mutant. These results indicate that the
PIAS-family proteins are capable of modifying Glis3 with SUMO1-3 and that
polySUMOylated Glis3 may be the target of proteasomal degradation.

Figure 4. PIASy and Ubc9 can modify Glis3 with SUMO1, SUMO2, and SUMO3. A.
HEK293T cells were transfected with FLAG Glis3 and Myc PIAS1 along with the
indicated GFP-tagged SUMO construct. Coimmunoprecipitations were performed using
mouse anti-GFP antibody and proteins were analyzed by Western blotting using mouse
anti-M2 FLAG antibody. B. BRIN-BD11 cells were transfected with FLAG empty vector,
FLAG Glis3, or a FLAG Glis3 Lys224/Lys430 double mutant and treated with 10 uM MG132 for 5
h prior to harvest. Co-immunoprecipitation was conducted using an anti-M2 FLAG antibody and
proteins were analyzed by Western blotting using a mouse anti-SUMO1 or anti-M2 FLAG. C.
HEK293T cells were transfected with the indicated plasmids. Co-immunoprecipitation was
performed using an anti-M2 FLAG antibody. Immunoprecipitated and input fractions were
analyzed by Western blotting using a rabbit anti-SUMO1 antibody, rat anti-HA antibody, or
mouse anti-M2 FLAG antibody and the appropriate HRP-conjugated secondary antibodies. D.

BRIN-BD11 cells were transfected with FLAG empty vector, FLAG Glis3, or a FLAG
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Glis3 Lys /Lys double mutant and treated with 10 uM MG132 for 5 h prior to
harvest. Co-IP was conducted as described in C.
The Glis3 N-Terminal Conserved Region is Required for Glis3 SUMOylation
To better understand what other regions of Glis3 might be required for PIASmediated SUMOylation, serial deletions of the Glis3 N-terminus were used in co-IP
experiments along with HA-SUMO and PIAS proteins. Deletion of the first 222 amino
acids of Glis3 had very little effect on Glis3 SUMOylation and both mono- and
diSUMOylated forms could be observed, similar to full-length Glis3 (Fig. 5A). Deletion
of the amino acids 1-388, including the previously described N-terminal conserved region
(NCR) located between amino acids 288-388 (ZeRuth et al., 2011) however resulted in a
complete loss of Glis3 SUMOylation despite the continued presence of Lys430. These
results suggested that the NCR might be required for SUMO modification of Glis3 by
PIAS-family proteins. Further deletion analyses showed that Lys430 could be
SUMOylated by PIAS1 despite deletions going all the way to the beginning of the NCR
at aa 288 (Fig. 5B) However, any subsequent deletions resulting in a loss of the Nterminal portion of the NCR resulted in a loss of Glis3 SUMOylation. These data suggest
SUMOylation of Glis3 by PIAS proteins might require the region of Glis3 between aa
288 and 333. GelC-MS/MS analysis had previously identified several phosphorylated
residues within the NCR (ZeRuth et al., 2015). To determine whether the
phosphorylation status of these residues influenced Glis3 SUMOylation Ser305, Ser307,
Ser310, and Ser343 were mutated to alanine either alone or in combination and the ability
of the mutants to be SUMOylated was assessed. Preventing phosphorylation did not
appear to significantly affect Glis3 SUMOylation (Fig. 5C). Likewise, phosphomimetic
mutation of Ser305, Ser307, and Ser310 to Asp did not appear to influence Glis3
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SUMOylation by PIASy (Fig. 5D). These findings strongly suggest the requirement of
the Glis3 NCR for modification by SUMO through a mechanism that does not rely on
phosphorylation of Ser305, Ser307, Ser310, or Ser343.

Figure 5. The NCR of Glis3 is required for SUMOylation. A-D. HEK293T cells were
transfected with the indicated plasmids. Co-immunoprecipitation was carried out using a
mouse anti-M2 FLAG antibody. Proteins were analyzed by Western blotting using a rat
anti-HA antibody or mouse anti-M2 FLAG or anti-Myc antibodies as indicated.
SUMOylation of Glis3 Decreases its Transcriptional Activity
Because the overall proportion of SUMOylated Glis3 to total Glis3 in the samples
was extremely low, measuring the effect of the modification on Glis3 function was
virtually impossible. To overcome this obstacle, OES cloning was performed to generate
chimeric proteins comprised of SUMO1 fused in-frame with Glis3 following amino acids
224 or 430 (Fig. 6A). To prevent the SUMO fusion constructs from being able to interact
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with other proteins targeted for SUMO modification, the SUMO insert was truncated
immediately prior to the C-terminal di-glycine motif. This truncation was performed
because this part of the protein plays an important role in associating with SUMOylation
substrates. Western blot analysis using an M2 FLAG antibody showed that both SUMO
fusion constructs produced a single band migrating slightly slower than unmodified Glis3
(Fig. 6B). To test the transactivation function of the SUMO fusion chimeras, they were
co-expressed in HEK293T cells along with a mIns2 reporter. As seen in Fig. 6C, similar
levels of activation were achieved using either of the SUMO fusion constructs relative to
unmodified Glis3. These results suggest that the fusion of SUMO within the N-terminus
of Glis3 does not appear to adversely affect protein folding, DNA binding, or the
recruitment of requisite co-activators. In contrast, when expressed in BRIN-BD11 cells,
both SUMO fusion chimeras were significantly less capable of activating the insulin
promoter suggesting that Glis3 SUMOylation may inhibit its function within the beta cell
environment (Fig. 6C). The reduced activity could not be attributed to defective nuclear
localization as both chimeric proteins were localized exclusively to the nucleus in BRINBD11 cells (Fig. 6D). To further examine the effect SUMO modification has on Glis3 in
beta cells, BRIN-BD11 cells were transfected with FLAG empty vector, FLAG Glis3, or
the Lys224/Lys430 double mutant, which is incapable of being modified by SUMO and
rIns2 expression was analyzed by RT-PCR. Remarkably, insulin message was > 100times higher in cells expressing the Glis3 mutant versus wild type Glis3 (Fig. 6E). The
expression of endogenous Glis3 was not significantly different between the samples and
using primers specific to FLAG-Glis3 it was demonstrated that expression of exogenous
Glis3 was also similar. The stability of Glis3 protein was also similar between the wild
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type and Lys mutant (Fig. 4B). Given the much higher activation capacity of the Glis3
Lys double mutant, it was expected that the SUMO-fusion constructs should have a
powerful negative influence on endogenous Ins2 activation. To test this idea, BRINBD11 cells were transfected with Glis3224:SUMO, Glis3430:SUMO, unmodified Glis3,
or empty vector and rIns2 was once again measured by RT-PCR. As expected, in-frame
insertion of SUMO1 in place of Lys224 resulted in an 80% reduction in Ins2 transcription
relative to cells expressing unmodified Glis3 while fusion of SUMO1 at Lys430 resulted in
a dramatic 99% reduction in activity (Fig. 6F). Glis3 transcripts were quantified and
found to be expressed at roughly equal levels between samples. These data establish that
SUMOylation may serve as a mechanism to negatively regulate insulin transcription by
Glis3.
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Figure 6. SUMOylation of Glis3 inhibits its ability to activate insulin transcription. A. Schematic
diagram of Glis3 and Glis3:SUMO fusion proteins generated by OES cloning. The conserved
SUMOylation motifs within the Glis3 N-terminus are indicated. B. FLAG-stained Western blot of
cell lysates from HEK293T cells expressing FLAG Glis3 or the indicated Glis3:SUMO fusion
protein. Molecular weight marker is indicated on the left. C. HEK293T cells were transfected
with p-mIP-696-Luc, pCMV-β-Gal, FLAG empty vector, p3xFLAG-CMV10-Glis3, or the
indicated Glis3:SUMO fusion construct. After 48 h, cells were harvested and assayed. * indicates
statistically different from FLAG Glis3, p < 0.01. D. BRIN-BD11 cells were grown on poly-

L-lysine coated glass coverslips for 48 h. The coverslips were stained with the indicated
antibody overnight at 4° C. Cells were stained with anti-mouse AlexaFluor 594
secondary antibody and mounted on glass microscope slides using Prolong Diamond
anti-fade with DAPI. E-F. BRIN-BD11 cells were transfected with the indicated FLAG empty
vector or FLAG-Glis3 construct. After 48 h, RNA was collected and the specified mRNA was
measured by qRT-PCR analysis. Each bar represents relative mRNA levels normalized to 18s
rRNA +/- SEM. * indicates statistically different value compared to empty vector control p <
0.01. # indicates statistically different value from both empty vector control and wild type Glis3,
p < 0.01.
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PIASy and Ubc9 Negatively Regulate Insulin Transcription Through Glis3Dependent and Glis3-Independent Mechanisms
To determine whether PIASy and Ubc9 similarly affected Glis3-mediated gene
activation in pancreatic beta cells, the mIns2 reporter was co-expressed in BRIN-BD11
cells along with Glis3, Ubc9, and PIASy. In complete contrast to what was observed in
HEK293T cells, in the BRIN-BD11 environment, Ubc9 and PIASy had a >70% decrease
in the activation of the insulin reporter by Glis3 when compared to Glis3 alone (Fig. 7A).
Moreover, reporter activity increased roughly two-fold compared to the wild type Glis3
when the Lys224/Lys430 double mutant was expressed in BRIN-BD11 cells indicating that
SUMOylation of Glis3 negatively affects its transactivation function. Unexpectedly
however, PIASy and Ubc9 similarly repressed activation of the reporter driven by the
Lys224/Lys430 double mutant or of Glis3 lacking its N-terminus indicating that the
repression was independent of Glis3 SUMOylation. Glis3 lacking its transactivation
domain (TAD)-containing C-terminus is capable of activating the mIns2 reporter roughly
7-fold in BRIN-BD11 cells (compared to > 30-fold activation observed using full-length
Glis3). Co-expression of Ubc9 and PIASy along with the C-terminal deletion mutant
similarly reduced reporter activity to baseline levels suggesting that the mechanism by
which the proteins reduce transcriptional activation might act on the Glis3 DNA-binding
domain (DBD). In order to test this hypothesis, reporter assays were conducted with
chimeric proteins containing the Glis3 TAD fused in-frame with the GAL4 DBD or the
Glis3 DBD fused in-frame with the GAL4-AD. The former was co-expressed in the
presence or absence of Ubc9 and PIASy with a modified mIns2 reporter in which the
GlisBS were mutated to GAL4-responsive UAS motifs. While the chimeric protein was
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capable of activating the reporter, Ubc9 and PIASy did not significantly affect activation
relative to empty vector controls (Fig. 7B). The chimera containing the Glis3 DBD and
the GAL4-AD was also capable of activating the mIns2 reporter but in contrast to the
former construct, Ubc9 and PIASy co-expression had a significant negative effect and
reduced reporter activity > 90%. As seen in HEK293T cells, the mechanism by which
Ubc9 and PIASy influence Glis3 activity appeared to be dependent on the transfer of
SUMO to substrate because co-expression of SENP1 virtually eliminated the repression
of activity (Fig. 7C). To examine whether decreased Glis3 transactivation function was
due to destabilization of Glis3 protein levels, BRIN-BD11 cells were transfected with
FLAG Glis3, Ubc9, PIAS1, or PIASy, alone or in combination and treated with
cycloheximide for 6 h before harvesting. Counterintuitively, co-expression of PIASy,
with or without Ubc9 appeared to stabilize Glis3 expression (Fig. 7D). In agreement with
the reporter assays, this stabilizing effect seemed to require the Glis3 DBD as it was
observed with Glis3 lacking its N-terminus but not when the N-terminus of Glis3 was
expressed alone (Fig. 7E). The increased stability to Glis3 provided by Ubc9 and PIASy
however did not appear to require Glis3 binding to DNA because the two proteins also
stabilized a Glis3 zinc finger mutant that cannot bind GlisBS (ZeRuth et al. 2015, Beak et
al. 2008). These data provide evidence that Ubc9 and PIASy negatively regulate Glis3mediated insulin activation while promoting stability of the Glis3 protein. When reporter
assays were performed in HEK293T cells using either the mIns2 promoter or an artificial
promoter driven by three tandem copies of the GlisBS (p3xGlisBS-Luc), co-expression of
PIASy and Ubc9 resulted in a sharp increase in Glis3-mediated reporter activation (Fig.
7F). Additionally, the mechanism by which Ubc9 and PIASy enhance Glis3
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transactivation function did not require Glis3 SUMOylation because the effect was still
observed when both Lys224 and Lys430 of Glis3 were mutated to Arg or when the entire
Glis3 N-terminus was deleted (Fig. 7G). The increased activity provided by Ubc9 and
PIASy did require Glis3 binding to DNA however because the proteins had essentially no
effect on reporter activity when co-expressed with a Glis3 ZFD mutant that is incapable
of binding DNA. These data are consistent with Glis3 stabilization in the presence of
PIASy and Ubc9 and suggest that inhibition of Glis3 transactivation function is specific
to the insulin promoter in the β-cell environment.
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Figure 7. PIASy and Ubc9 repress Glis3-mediated insulin transcription in BRIN-BD11
cells. A. BRIN-BD11 cells were transfected with p-mIP-696-Luc, pCMV-β-Gal, FLAG
empty vector or the indicated FLAG Glis3 construct along with Myc empty vector or
MYC PIASy and Ubc9. After 48 h, cells were harvested and assayed. * indicates
statistically different than corresponding Myc empty vector controls. p < 0.01. B. BRINBD11 cells were transfected with p-mIP-696-Luc or p-mIP(UAS)-Luc as indicated along
with pCMV-β-Gal. Cells were also transfected with the indicated Gal4:Glis3 chimeric
fusion protein and either Myc empty vector or Myc PIASy and Myc Ubc9. After 48 h,
cells were harvested and assayed for luciferase and b-galactosidase activity and the
normalized relative luciferase activity (nRLU) was calculated. Black bars represent
relative proportion of luciferase expression from cells expressing Myc PIASy and Myc
Ubc9 compared to corresponding samples expressing Myc empty vector (grey bars) +/SEM. * indicates statistically different from mIP-696 and mIP(UAS) empty vector
controls. p < 0.01. C. BRIN-BD11 cells were transfected with p-mIP-696-Luc, pCMV-βGal, and the indicated plasmids. After 48 h, cells were harvested and assayed. D-E.
BRIN-BD11 cells were transfected with the indicated plasmids and treated with 10 ug/ml
cycloheximide for 5 h prior to harvest. Proteins were separated by SDS-PAGE and
analyzed by Western blotting using the specified antibodies. GAPDH is shown as an
internal control. F. HEK293T cells were transfected with p-3xGlisBS-Luc, pCMV-β-Gal,
FLAG empty vector, p3xFLAG-CMV10-Glis3, Myc-Ubc9, or Myc-PIASy as indicated.
After 48 h, cells were assayed for luciferase and -galactosidase activity and the
normalized relative luciferase activity (nRLU) was calculated and plotted. G. HEK293T
cells were transfected with the indicated FLAG empty vector or FLAG Glis3 construct
along with Myc empty vector, MYC PIAS1 and Ubc9, or MYC PIASy and Ubc9. After
48 h, cells were harvested and assayed.
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SUMOylation of MafA by PIASy and Ubc9 Neutralizes Synergism with Glis3
To see if the repressive effect of Ubc9 and PIASy was unique to the mIns2
promoter, a luciferase reporter driven by three tandem copies of the GlisBS was
transfected in BRIN-BD11 cells along with Glis3, Ubc9, and PIASy. In contrast to what
was observed using the mIns2 reporter, 3xGlisBS-Luc activity was modestly enhanced by
Ubc9 and PIASy indicating that the inhibitory effect requires additional features specific
to the insulin promoter (Fig. 8A). It has previously been demonstrated that Glis3 acts
synergistically at the insulin promoter with several other key insulin regulatory factors
including MafA (ZeRuth et al., 2013; Yang et al., 2009). Additionally, preceding studies
have shown that SUMOylation of MafA negatively affects its transactivation function at
the insulin promoter (Kanai et al., 2010; Shao and Cobb, 2009). In order to determine
whether Ubc9 and PIASy were capable of transferring SUMO to MafA, FLAG-MafA
was immunoprecipitated in HEK293T cells in the presence or absence of exogenous
Ubc9 and PIASy and blots were stained with an antibody targeting SUMO1. While
SUMOylated MafA was not detected with the addition of Ubc9 and PIASy alone, the coexpression of the proteins along with exogenous HA-SUMO1 significantly enhanced
MafA SUMOylation (Fig. 8B) similar to what was seen with Glis3. MafA was further
found to be SUMOylated by endogenous SUMO2/3 in BRIN-BD11 cells when coexpressed with PIASy (Fig. 8C). To assess the effect of Ubc9 and PIASy on Glis3:MafA
synergism, reporter assays were conducted in HEK293T cells co-expressing a mIns2
reporter along with Glis3 and MafA in the presence or absence of Ubc9 and PIASy. Ubc9
and PIASy had opposite effects on the transcription factors in HEK293T cells resulting in
a > 50% decrease in MafA-mediated activation and a significant enhancement of
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activation by Glis3, as shown previously (Fig. 8D). The positive effect of Ubc9 and
PIASy on Glis3 transactivation function was essentially lost however when Glis3 was coexpressed with MafA. In BRIN-BD11 cells, Ubc9 and PIASy similarly reduced
activation of the mIns2 reporter by Glis3 or MafA approximately 75%. Overexpression
of Ubc9 and PIASy reduced activity of the mIns2 reporter by roughly 50% when coexpressed with empty FLAG vector implicating negative regulation of endogenous
transcription factors in the beta cells, presumably Glis3 and MafA. To determine if the
negative influence of Ubc9 and PIASy on Glis3 function in BD11 cells was due to
negative regulation of endogenous MafA, reporter assays were conducted in which the
ability of Glis3 to activate the mIns2 promoter in the presence of exogenous Ubc9 and
PIASy was assessed with two different concentrations of FLAG-MafA. While Ubc9 and
PIASy significantly reduced Glis3-mediated activation of the insulin promoter, increasing
MafA expression was able to rescue activity (Fig. 8E). Increasing MafA expression also
restored diminished reporter levels when Ubc9 and PIASy were co-expressed with FLAG
empty vector (data not shown). Finally, mutation of the MafA enhancer element (C-box)
within the mIns2 reporter had a similar repressive effect on Glis3-mediated
transactivation (Fig. 8F). Co-expression of Ubc9 and PIASy led to an additional decrease
in activity suggesting the decreased levels of activation likely do not function exclusively
through disrupting Glis3:MafA synergism.
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Figure 8. SUMOylation of MafA disrupts synergism with Glis3 at the insulin promoter. A.
BRIN-BD11 cells were transfected with p-3xGlisBS-Luc, pCMV-β-Gal, FLAG empty vector,
p3xFLAG-CMV10-Glis3, Myc-Ubc9, or Myc-PIASy as indicated. After 48 h, cells were
harvested and assayed. B. HEK293T cells were transfected with the indicated plasmids and
harvested after 48 h. Co-immunoprecipitation was performed using an anti-M2 FLAG antibody.
Immunoprecipitated and input fractions were analyzed by Western blotting using a rabbit antiSUMO1 antibody, mouse anti-Myc antibody, or mouse anti-M2 FLAG antibody and the
appropriate HRP-conjugated secondary antibodies. C. BRIN-BD11 cells were transfected with
the indicated plasmids and harvested after 48h. Co-immunoprecipitation was performed using
anti-M2 FLAG antibody. Immunoprecipitated fractions were analyzed by Western blot using
rabbit anti-SUMO1 antibody, mouse anti-M2 FLAG antibody, or mouse anti-SUMO2/3 antibody.
D. HEK293T (Left) or BRIN-BD11 (Right) cells were transfected with p-mIP-696-Luc, pCMVβ-Gal, and the indicated FLAG empty vector, Glis3, or MafA plasmids. Cells were additionally
transfected with either Myc empty vector or Myc PIASy and Myc Ubc9. After 48 h, cells were
harvested and assayed for luciferase and -galactosidase activity and the normalized relative
luciferase activity (nRLU) was calculated. Black bars represent relative proportion of luciferase
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expression from cells expressing Myc PIASy and Myc Ubc9 compared to corresponding samples
expressing Myc empty vector (grey bars) +/- SEM.. E. BRIN-BD11 cells were transfected with
p-mIP-696-Luc, pCMV-β-Gal, and FLAG empty vector, FLAG-Glis3, and Myc-PIASy and Ubc9
as indicated. Cells were transfected with an increasing concentration of FLAG-MafA where
indicated by the shaded triangle. After 48 h, cells were harvested and assayed F. BRIN-BD11
cells were transfected with p-mIP-696-Luc or a mutant with the C-box mutated, pCMV-β-Gal,
and FLAG empty vector, FLAG-Glis3, and Myc-PIASy and Ubc9 as indicated. After 48 h, cells
were harvested and assayed. * indicates statistically different than Myc empty vector controls. p <
0.01.

Glis3 is SUMOylated Under Conditions of Chronic Hyperglycemia in BRIN-BD11
Cells
Chronic exposure of β cells to high levels of glucose has previously been
associated with decreased levels of insulin transcription mediated in part by decreased
binding of MafA and Pdx1 to the insulin promoter (Harmon et al. 2005, Park et al. 2007,
Lee et al. 2012). This so-called glucose toxicity is also accompanied by decreased levels
of MafA transcription (Olson et al. 1993, Sharma et al. 1995, Poitout et al. 1996). BRINBD11 cells were exposed to either 3 mM glucose, corresponding to normal physiological
blood glucose levels, or 25 mM glucose, corresponding to hyperglycemic conditions, for
48 hours and gene expression was analyzed by RT-PCR. As shown previously in other β
cell lines, under conditions of chronic hyperglycemia insulin transcription was severely
reduced (Fig. 9A). Interestingly, while MafA transcription was reduced by approximately
40% under hyperglycemic conditions, Glis3 transcripts were reduced nearly 70%
suggesting that Glis3 is also affected by glucose toxicity. No statistically significant
change in either PIAS1 or PIASy expression was observed in response to glucose levels.
To determine whether PIAS-proteins were regulated posttranslationally in response to
glucose, Western blots were performed from BRIN-BD11 cells grown under high or low
glucose conditions. While PIAS1 expression was similar under both conditions, a higher
molecular weight band corresponding to a previously identified SUMOylated form of
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PIASy (Ihara et al. 2005) was significantly increased following exposure to 25 mM
glucose (Fig. 9B). Glis3 expression was also examined at the protein level using BRINBD11 cells stably expressing FLAG Glis3 grown under low or high glucose
concentrations. The results indicate that Glis3 protein expression is stabilized under
chronically high glucose conditions (Fig. 9C). Importantly, under high glucose
conditions, several higher molecular weight bands were observed that might represent
SUMOylated Glis3. MafA SUMOylation was reported in β cells exposed to oxidative
stress suggesting that modification of MafA by SUMO may serve as a mechanism to
reduce insulin transcription under hyperglycemic conditions (Shao and Cobb 2009). To
determine whether Glis3 is SUMOylated under conditions of glucose toxicity, anti-M2
FLAG antibody was used to immunoprecipitate proteins in BRIN-BD11 cells stably
expressing FLAG Glis3 or empty vector grown under different glucose concentrations.
The results indicated that SUMO2/3 modified Glis3 increased under high glucose
conditions in agreement with the Western blot data (Fig. 9D).
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Figure 9. Glis3 is SUMOylated under conditions of chronic hyperglycemia in BRINBD11 cells. A. BRIN-BD11 cells were exposed to either 3 mM or 25 mM glucose for 48
hours. RNA was collected from cell lysates, and cDNA was generated. RT-PCR was used
to analyze the relative amounts of indicated transcripts. B. BRIN-BD11 cells were grown
as described in A. Proteins were separated by SDS-PAGE and analyzed by Western blot
using rat anti-PIAS1 antibody or rabbit anti-PIASy antibody. GAPDH is shown as an
internal control. C. BRIN-BD11 cells stably expressing Glis3 were grown under
conditions described in A. Proteins were separated by SDS-PAGE and analyzed by
Western blot using mouse anti-M2 FLAG antibody. GAPDH is shown as an internal
control. D. BRIN-BD11 cells were grown as described in A. Proteins were separated by
SDS-PAGE and analyzed by Western blot using mouse anti-M2 FLAG, rabbit antiSUMO1 antibody, or mouse anti-SUMO2/3 antibody.
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Discussion and Future Direction
These studies have shown that PIAS-family proteins are capable of modifying the
transcription factor, Glis3 with the small ubiquitin-like modifier, SUMO1, SUMOL2, and
SUMO3. Overexpression of PIASy in combination with Ubc9 had a significant negative
influence on the transactivation function of Glis3 and greatly diminished its ability to
activate Ins2 expression in BRIN-BD11 cells. Data demonstrating that mutation of both
SUMO targeted lysine residues to arginine resulted in a 100-fold increase in insulin
transcription compared to wild type Glis3 is consistent with the idea that SUMOylation
has an inhibitory effect on Glis3-mediated transactivation of insulin. The increased level
of insulin transcription is not likely attributable to the creation of novel methylation sites
that might subsequently affect transactivation function because similar observations were
made when the Lys residues were mutated to Ala (data not shown).
Despite the magnitude of the increase in insulin transcription when the Glis3
SUMOylation motifs were mutated, only a very small proportion of immunoprecipitated
Glis3 was SUMOylated in cells overexpressing Glis3. It is not currently clear why such a
small fraction of Glis3 is SUMOylated but it may be due to a requirement for factors that
are too limited to handle the amount of Glis3 present in an overexpression system. It is
additionally possible that Glis3 must first be posttranslationally modified prior to
SUMOylation or that SUMOylation of Glis3 is dynamic and deSUMOylating factors
such as SENPs are rapidly reversing SUMOylation. Finally, the low proportion of
SUMOylated Glis3 may be due to the fact that SUMOylated Glis3 is rapidly turned over.
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Indeed, we found that Glis3 SUMOylation could be reversed by overexpression of
SENP1 and that Glis3 SUMOylated by SUMO2/3 was the target of proteolytic
degradation.
In order to better understand the effect of SUMOylation on Glis3 function,
Glis3:SUMO fusion chimeras, which should approximate SUMOylated Glis3, were
created and analyzed. These experiments demonstrated a profound negative regulatory
consequence of Glis3 SUMOylation that appeared to be specific to Glis3-mediated
activation of the preproinsulin (Ins2) promoter in a pancreatic β cell environment. The
mechanism by which SUMOylation regulates Glis3 function is not clear at this time. The
SUMO fusion with Glis3 was unlikely to have affected Glis3 function by causing
improper folding or inhibiting binding to GlisBS because the constructs activated a mIns2
reporter in HEK293T cells similarly to full-length, wild type Glis3. The Glis3:SUMO
chimeras additionally did not exhibit any defect in their ability to localize to the nucleus
nor were protein expression levels significantly different. This suggests that the addition
of SUMO moieties to the Glis3 N-terminus may compete with other posttranslational
modifications such as phosphorylation or acetylation that may be associated with positive
transcriptional regulation specifically within β-cells. It is also probable that SUMOylation
of Glis3 interferes with Glis3 recruitment of pancreatic β-cell-specific co-activators.
Indeed, previous reports have shown that the ability of Glis3 to activate insulin
transcription was severely compromised when binding by Pdx1, NeuroD1, and MafA to
the Ins2 promoter was abrogated (ZeRuth et al. 2013).
Other than negatively regulating Glis3 function by the direct attachment of
SUMO to lysine residues within the Glis3 N-terminus, PIASy and Ubc9 had an additional
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indirect role in regulating Glis3 independent of Glis3 SUMOylation. While the inhibitory
effect of the proteins on Glis3 did not require modification of Glis3 with SUMO, it did
appear to require SUMOylation of other unknown targets because the inhibition was
reversed by the overexpression of the SUMO protease, SENP1. As seen with Glis3
SUMOylation, the indirect inhibition afforded by PIASy and Ubc9 was specific to β cells
and was not observed in HEK293T cells. This suggested that PIASy and Ubc9 were
likely modifying a β cell specific target. Previous studies have shown that the
transcription factor, Pdx1, was SUMOylated in pancreatic β cells; however, the
modification resulted in increased nuclear localization and positive regulation of insulin
transcription (Kishi et al., 2003). In contrast, SUMOylation negatively regulated the
transcriptional activity of the β cell transcription factor, MafA through an unknown
mechanism (Kanai et al. 2010, Shao and Cobb 2009). In this report, evidence was
provided demonstrating that PIASy and Ubc9 were capable of modifying MafA with
SUMO1 as well as SUMO 2/3. In addition, excess MafA was able to reverse the negative
effect of PIASy and Ubc9 on Glis3-mediated insulin transcription and mutation of the
MafA binding site within the insulin promoter had an inhibitory effect on transcriptional
activation by Glis3 to a similar extent as observed with overexpression of PIASy and
Ubc9. Collectively, these data make it tempting to speculate that PIASy and Ubc9 may
inhibit synergism between MafA and Glis3 by SUMOylating each protein respectively. A
previous report suggested a direct or indirect interaction between Glis3 and MafA (Yang
et al. 2009), while another showed that Glis3 may form a complex with MafA, Pdx1, and
NeuroD1 through co-recruitment of CBP/p300 (ZeRuth et al. 2013). It is possible that
SUMOylation of Glis3 and MafA interferes with these events and prevents synergistic
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activation of target genes such as insulin. Future studies are required to test these and
other mechanisms by which SUMOylation could be affecting synergism between
transcription factors.
Chronic exposure of β cells to high levels of glucose has previously been
associated with decreased levels of insulin transcription mediated in part by decreased
binding of MafA and Pdx1 to the insulin promoter (Harmon et al. 2005, Park et al. 2007,
Lee et al. 2012). Much of the decrease in insulin transcription was likely due to the
observed transcriptional downregulation of Pdx1 and MafA. Glis3 was also seen to be
transcriptionally downregulated in BRIN-BD11 cells grown under conditions of chronic
hyperglycemia (GTZ unpublished data). However, MafA SUMOylation was reported in β
cells exposed to oxidative stress suggesting that modification of MafA by SUMO may
additionally serve as a mechanism to reduce insulin transcription under hyperglycemic
conditions (Shao and Cobb 2009). Under conditions of chronically elevated glucose in
BRIN-BD11 cells, we observed increased expression of a high molecular weight species
of PIASy that correlated with increased SUMOylation of exogenous Glis3 by SUMO2/3.
The absence of a reliable Glis3 antibody restricts the ability to determine whether Glis3 is
SUMOylated under conditions of chronic hyperglycemia but further studies will be
required to examine whether oxidative stress promotes SUMOylation of PIASy or Glis3
and the subsequent downregulation of insulin transcription.
In HEK293T cells as well as in BRIN-BD11 cells expressing a generic reporter
controlled by tandem copies of the GlisBS, PIASy and Ubc9 had a positive effect on
Glis3-directed transcription that was again independent of Glis3 SUMOylation. The
mechanism underlying this positive effect is not currently understood. PIASy and Ubc9
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may promote SUMOylation of the general transcriptional machinery that consequently
increases Glis3-mediated gene activation. Indeed, SUMO has been previously shown to
positively influence RNA polII-associated GTFs through several different mechanisms
(Chymkowitch et al. 2015). Moreover, SUMOylation of Sp1 has been shown to both
positively and negatively regulate its recruitment of CBP/p300 at different times during
development demonstrating dual roles of SUMO modification within the same protein
target (Gong et al. 2014). There may also be a positive effect from PIASy and Ubc9 coexpression with Glis3 due to a general increase in protein stability. Previously, the tumor
suppressor, SUFU, has been shown to have a similar effect on Glis3 in that it repressed
insulin activation by Glis3 in INS1 cells while simultaneously stabilizing Glis3 protein
levels (ZeRuth et al. 2011). Together, these studies suggest that Glis3 protein turnover
may be linked to target gene activation.
Interaction with SUFU required a region of the N-terminus of Glis3 termed the Nterminal conserved region (NCR) due to its high levels of homology with the N-termini
of Gli1, Gli2, and Gli3, the downstream effectors of hedgehog signaling that are
specifically responsible for activating or repressing target genes (ZeRuth et al. 2011).
Interestingly, modification of Glis3 with SUMO by PIAS-family proteins also required
this region, which is located in-between the two SUMOylated lysine residues of Glis3. It
is not clear whether the region is utilized in mediating interaction between Glis3 and
PIAS proteins or whether posttranslational modifications within the region are required
prior to SUMO modification. Others have reported that the N-terminus of Gli-family
proteins can be SUMOylated by PIAS1 (Cox et al. 2010). Additional studies would be
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required to determine whether the NCR of Gli1-3 is required for their modification by
SUMO and whether PIASy and Ubc9 influence Glis3 interaction with SUFU.
Collectively, these studies implicate SUMOylation as a mechanism that may be
used to negatively regulate insulin transcription through inhibition of Glis3 and MafA
transactivation function. Reversible posttranslational modifications of transcription
factors could serve as an effective means to rapidly respond to environmental cues such
as serum glucose levels. These modifications might also be a source of dysfunction in
instances such as oxidative stress where their negative influence on insulin transcription
can contribute to disease states such as diabetes. Investigation of Glis3 expression and
posttranslational modifications under conditions of chronic hyperglycemia and oxidative
stress will be a continued focus of research into the future.
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Appendix
Recipes:
10X Phosphate Buffered Saline (PBS)
For 500 ml
NaCl – 1.37 M

40 g

KCl – 27 mM

1g

Na2HPO4 – 100 mM

7.2 g

KH2PO4 – 18 mM

1.2 g

Dissolve reagents in 400 ml of ddH2O. Adjust pH to 7.4 with HCl. q.s to 500 ml with
ddH2O. Sterilize by autoclaving. Store at RT.

RIPA Buffer
For 100 ml
Tris – 25 mM

2.5 ml (1M)

NaCl – 150 mM

3 ml (5M)

EDTA - 1 mM

200 ul (0.5M)

EGTA – 1 mM

200 ul (0.5M)

NaMolybdate – 20 mM

2 ml (1M)

Nonidet P-40 – 0.5%

5 ml (10%)

ddH2O

87.1 ml
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Mix together ingredients. Store at RT. Add protease inhibitor cocktail immediately before
use. NP-40 and NaCl concentrations can be adjusted to reduce/increase stringency. 1%
SDS can be added before use.
LB Medium

For 500 ml
Tryptone –

5g

Yeast extract –

2.5 g

NaCl –

5g

Agar (if for plates) –

7.5 g

Mix ingredients in 300 ml of water by stirring. Sterilize by autoclaving. Cool to ~55° C
(cool enough to touch) before adding antibiotic.

Protocols
Co-IP
1. Ensure that cells are at 70-80% confluency
2. Begin with 4 sets of microcentrifuge tubes
a. The number of tubes in a set will correspond to the number of samples
3. Also begin with two 25 ml conical tubes
a. One will have 500 μl of RIPA buffer per sample (round up to next largest
measurement)
i. It will also have 10 μl/ml of protease inhibitor cocktail
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b. The other will have 700 μl of PBS per sample + 100μl
i. Also add protease inhibitor cocktail at 10 μl/ml
4. Set centrifuge to 4°C
5. Set heat block to 70°C
6. Have small beaker with regular PBS placed in ice
7. Gently pour media out of tray
8. Gently wash cells with ice cold PBS (from beaker)
a. Pour down side of each well
b. Repeat
c. Pour out in sink
9. Aspirate excess PBS
10. Add 500 μl RIPA buffer to each well
a. Suck up and wash down to the corner of well held to an angle
b. Add each lysate to a pre-chilled microcentrifuge tube
c. Leave on ice for about 10 minutes
11. Get metal beads out of 4°C
a. Rock on cradle to get in solution
12. Prepare antibody
a. Dilute appropriately in 0.01% PBST
13. Place 30 μl of bead solution in a new tube for each sample
14. Place tubes on the magnet rack
15. Suck out clear liquid
16. Add 200 μl of diluted antibody solution to each tube
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a. Suck in and out of pipette to get beads back in solution
17. Place in rotator for 15-30 minutes
18. Place lysate tubes in refrigerated centrifuge
a. 10 minutes at 4°C at about 1600 rcf
19. Add 12.5 μl of 4x buffer and 37.5 μl of lysate in each of what will be the input
tubes
a. Pump up and down with pipette to mix
b. Poke hole in top of each tube
20. Place input tubes in heat block for 10 minutes (70°C)
21. Place bead tubes back on magnet tray and suck out clear liquid
22. Wash these tubes to get rid of excess antibody with 200 μl 0.01% PBST
a. Pump up and down to get back into solution
b. Place back on magnet and suck out of tube
23. Use about 410 μl of lysate for each tube
24. Incubate IP tubes on the rotator for about 30 minutes
25. Take inputs out of the heat block
a. Place in -20°C freezer
26. Set heat block to 95˚C
27. Make new buffer for IP tubes
a. Dilute 4x buffer to 1x with RIPA + Protease inhibitor (1:3 ratio
respectively)
28. Set up polyacrylamide gel
29. Take IP tubes off of rotator
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a. Place on magnet
b. Suck out clear liquid
30. Wash beads back into solution with 200 μl PBS + Protease inhibitor
a. Place back on magnet
b. Suck out PBS
c. Repeat 2 more times
31. Add 100 μl of PBS to each tube
a. Get beads in solution and transfer to new tubes
b. Put on magnet and suck out PBS
32. Load 40 μl of the prepared 1x buffer to each tube with beads
a. Poke hole in lids
b. Place in heat block (95°C for 5 minutes)
33. Place tubes on magnet
34. Load gel(s) (30 μl)
a. Use 5 µl molecular weight marker
35. Run gel until blue gets to the bottom (165 volts until blue reaches bottom)
36. Transfer gel to membrane (20 volts for one hour)
37. Block using 5% dry milk in 1x TTBS
a. Use about 10 ml per block usually
b. 30 min to an hour
38. Follow block up with primary and secondary antibody staining
a. Primary staining
i. Overnight in fridge or 1 hour room temp
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b. Wash 3x 10 min with 1x TTBS next day
c. Secondary stain one hour at room temp
d. Wash 3x 10 min with 1x TTBS
39. Use 1:1 ratio of developing solutions (1500 μl per blot)
a. Allow to develop for 1 minute

Luciferase Assay
1. Triplicate sample tubes
2. Make lysis buffer
a. 125 μl/well for HK293 cells
b. Round to next hundred
c. Dilute 5x  1x (1:4)
3. Get PBS to wash
4. Thaw luciferase assay substrate
5. Get plate (96 wells) ready
6. Wash
a. Dump off media
b. Draw 1 ml PBS
i. Use about 300 μl to wash each well
c. Perform total of 2 washes and aspirate
7. Add 125 μl of lysis buffer to each well
a. Use backwards pipet tip to scrape cells to bottom of well
8. Transfer the lysate to tubes
9. Centrifuge 2 minutes at max speed
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10. Add 20 μl of lysate per sample
a. Each loaded in duplicate for luciferase and β-gal
11. β-gal solution
a. Use 50 μl per well for half of the wells
i. Round up amount collected
b. Use β-galactosidase to substrate in a (49:1) ratio respectively
i. Allow to incubate for about 30 minutes
12. Add 50 μl per well of luciferase assay substrate
13. Open Lumate manager on computer
14. Go to test  read plate (rlu) type last well to read
15. Graph data and use t-test to analyze significance
OES Cloning
1. First reaction is set up using 100ng of the largest piece and equimolar rations of
all other pieces. A proofreading polymerase should be used. The total reaction
volume is 50µl.
2. The reaction involves a 95º initial denaturation step, then 95º for 30 seconds,
annealing for 30 seconds, and elongation for the appropriate amount of time
repeated 30 times with a final 10 minute elongation step.
3. The second reaction is set up using primers for either end of the entire desired
clone and 5µl of the first reaction. A standard Taq should be used if this is to be
followed by TOPO-TA cloning.
4. The reaction parameters for the second reaction will be the same as the first
reaction.
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Plasmids Generated

PIASy/PIAS1/Ubc9

pCMV-Myc

Glis3-SUMO
Fusion

pCRii-TOPO

